PulseAugur
EN
LIVE 01:56:51
中文(ZH) 九典制药：获得西尼地平片及氨溴特罗口服溶液药品注册证书

Jiudian Pharmaceutical receives drug approvals for hypertension and respiratory treatments

By PulseAugur Editorial · [1 sources] ·

Jiudian Pharmaceutical has received drug registration certificates from the National Medical Products Administration for Cilnidipine Tablets and Ambroxol Oral Solution. The Cilnidipine Tablets are used for treating hypertension, and Jiudian Pharmaceutical is the first domestic company to pass or be deemed to have passed the consistency evaluation for generic drugs. Ambroxol Oral Solution is commonly used for respiratory conditions such as cough and difficulty expectorating. AI

RANK_REASON This is a product release for a pharmaceutical company, not a frontier AI release.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Jiudian Pharmaceutical receives drug approvals for hypertension and respiratory treatments

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
This is a product release for a pharmaceutical company, not a frontier AI release.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
132 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Jiudian Pharmaceutical: Obtains Drug Registration Certificates for Cilnidipine Tablets and Ambroxol Oral Solution

    36氪获悉，九典制药公告，公司近日收到国家药监局下发的《药品注册证书》，涉及西尼地平片（规格10mg）和氨溴特罗口服溶液(规格100ml)两个药品。西尼地平片适用症是用于高血压患者的治疗，截至本公告日，西尼地平片国内共有4家企业取得了药品注册证书，公司为国内第1家通过或视同通过仿制药质量和疗效一致性评价的企业；氨溴特罗口服溶液常用于治疗急、慢性呼吸道疾病（如急、慢性支气管炎、肺气肿等）引起的咳嗽、痰液黏稠、排痰困难、喘息等。

RELATED ENTITIES

RELATED TOPICS